Association of urinary activity of MMP-9 with renal impairment in Mexican patients with type 2 diabetes mellitus.

Autor: García-Tejeda AU; Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México., Sampieri CL; Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México., Suárez-Torres I; Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México., Morales-Romero J; Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México., Demeneghi-Marini VP; Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 66. Delegación Veracruz Norte, Xalapa, Veracruz, México., Hernández-Hernández ME; Secretaría de Salud del Estado de Veracruz, Unidad de Inteligencia Epidemiológica en Salud, Xalapa, Veracruz, México., Rodríguez-Hernández A; Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 10, Xalapa, Veracruz, México.
Jazyk: angličtina
Zdroj: PeerJ [PeerJ] 2018 Dec 06; Vol. 6, pp. e6067. Date of Electronic Publication: 2018 Dec 06 (Print Publication: 2018).
DOI: 10.7717/peerj.6067
Abstrakt: Background: Diabetic kidney disease is the most common cause of chronic kidney disease (CKD). An early event in diabetic kidney disease is alteration of the glomerular basement membrane and the mesangial expansion. Matrix metalloproteinases (MMP) are a family of endopeptidases responsible for controlling the pathophysiological remodeling of tissues, including renal tissues. MMP-9 in human urine has been proposed as a marker of diabetic nephropathy and urinary tract infections (UTI).
Methods: A cross-sectional study was conducted in type 2 diabetes mellitus (T2DM) patients who receive first level medical attention in Mexico. We used ELISA to measure MMP-9 levels in the urine of subjects with T2DM ≥ 18 years of age, who fulfilled the clinical requirements for calculation of glomerular filtration rate (GFR), according to the K/DOQI guide, in an attempt to identify whether MMP-9 levels in T2DM differ in patients with and without renal impairment. Univariate and multivariable analyses were performed in order to identify the association between MMP-9 and renal impairment.
Results: Included in the study were 34 (45%) subjects with renal impairment and 42 (55%) without. In the group with renal impairment, 10 subjects corresponded to stages 1-2 and 24 subjects corresponded to stage 3, according to their values of GFR and urinary albumin, following that proposed by the K/DOQI. No differences were found relating to sex, age, having or not having a partner, education, being able to read and write a message and duration of T2DM. Moreover, no differences were found between the groups in terms of weight, height, body mass index, waist size in general and frequency of UTI. In contrast, serum creatinine and urinary albumin were higher in the group with renal impairment, while GFR was greater in the group without renal impairment. Levels of MMP-9 were greater in women compared to men. Through univariate analysis in the general population, the presence of MMP-9 and that of its percentile 90 (P 90 ) P 90 were associated with the renal impairment group; however, in patients without UTI, only the presence of MMP-9 was associated with the renal impairment group, and no association was found with its P 90 . Multivariate analysis revealed an association between MMP-9 and its P 90 with renal impairment.
Discussion: It is necessary to validate sensitive and non-invasive biological markers of CKD. We demonstrate that the presence and P 90 of urinary MMP-9 are associated with renal impairment in Mexican patients with T2DM. While high levels of MMP-9 were associated to females and UTI, the presence of UTI was not associated with the incidence of renal impairment.
Competing Interests: The authors declare that they have no competing interests.
Databáze: MEDLINE
Externí odkaz: